Brainomix has partnered with Bridge Biotherapeutics to deliver AI imaging biomarker analysis within the Phase II study of novel autotaxin inhibitor BBT-877 in idiopathic pulmonary fibrosis (IPF).
Under the partnership, Brainomix will leverage its e-ILD technology (automated artificial intelligence software) which has been trained to process high resolution chest CT (HRCT) data in patients with interstitial lung diseases.
The data will be used to explore the efficacy of BBT-877 and to demonstrate the value that Brainomix AI-powered imaging biomarkers offer as new endpoints for future IPF clinical trials.
Clinical trials in IPF commonly rely on serial physiological measurement of forced vital capacity (FVC) as trial endpoints, which can be highly variable from day-to-day for any individual patient. Automated AI-powered quantitative imaging could significantly improve trial design, improve the chances of identifying a positive treatment response and accelerate the availability of new treatments.
Brainomix initially developed an automated AI solution for stroke assessment (e-Stroke) and has since expanded into other areas where there are similar unmet needs.
“AI-powered imaging is becoming an increasingly critical component of studies in IPF and more broadly non-IPF interstitial lung diseases, where it has the potential to improve trial insights, and to complement existing trial methodology and endpoints,” said Dr Peter George, Medical Director (Respiratory) at Brainomix and Clinical Lead of the Interstitial Lung Disease Unit at the Royal Brompton Hospital.
